{"id":"https://openalex.org/W2186501901","doi":"https://doi.org/10.1182/blood.v122.21.1554.1554","title":"Hematologic Response To Oral Azacitidine (CC-486) In Subjects With WHO-Defined RAEB-1 Or RAEB-2 Myelodysplastic Syndromes (MDS)","display_name":"Hematologic Response To Oral Azacitidine (CC-486) In Subjects With WHO-Defined RAEB-1 Or RAEB-2 Myelodysplastic Syndromes (MDS)","publication_year":2013,"publication_date":"2013-11-15","ids":{"openalex":"https://openalex.org/W2186501901","doi":"https://doi.org/10.1182/blood.v122.21.1554.1554","mag":"2186501901"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v122.21.1554.1554","doi":"https://doi.org/10.1182/blood.v122.21.1554.1554","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v122.21.1554.1554","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5061026876","display_name":"Guillermo Garcia\u2010Manero","orcid":"https://orcid.org/0000-0002-3631-2482","observed_orcids":["https://orcid.org/0000-0002-3631-2482"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Guillermo Garcia -Manero","raw_affiliation_strings":["Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA,","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049400849","display_name":"Michael Robert Savona","orcid":"https://orcid.org/0000-0003-3763-5504","observed_orcids":["https://orcid.org/0000-0003-3763-5504"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Savona","raw_affiliation_strings":["Sarah Cannon Research Institute, Nashville, TN, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, TN, USA,","institution_ids":["https://openalex.org/I4210100810"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101760493","display_name":"Steven D. Gore","orcid":"https://orcid.org/0000-0002-3649-8758","observed_orcids":["https://orcid.org/0000-0002-3649-8758"]},"institutions":[{"id":"https://openalex.org/I145311948","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95","country_code":"US","type":"education","lineage":["https://openalex.org/I145311948"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven D. Gore","raw_affiliation_strings":["The Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, USA,","institution_ids":["https://openalex.org/I145311948"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042492175","display_name":"Christopher Ramin Cogle","orcid":"https://orcid.org/0000-0001-5422-6863","observed_orcids":["https://orcid.org/0000-0001-5422-6863"]},"institutions":[{"id":"https://openalex.org/I2800717037","display_name":"University of Florida Health","ror":"https://ror.org/04tk2gy88","country_code":"US","type":"education","lineage":["https://openalex.org/I2800717037","https://openalex.org/I33213144"]},{"id":"https://openalex.org/I33213144","display_name":"University of Florida","ror":"https://ror.org/02y3ad647","country_code":"US","type":"education","lineage":["https://openalex.org/I33213144"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christopher R. Cogle","raw_affiliation_strings":["Department of Medicine, Division of Hematology/Oncology, University of Florida, Gainesville, FL, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Division of Hematology/Oncology, University of Florida, Gainesville, FL, USA,","institution_ids":["https://openalex.org/I2800717037","https://openalex.org/I33213144"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085156317","display_name":"Paul Conkling","orcid":"https://orcid.org/0009-0001-5624-8799","observed_orcids":["https://orcid.org/0009-0001-5624-8799"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Paul Conkling","raw_affiliation_strings":["Virginia Oncology Association, Norfolk, VA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Virginia Oncology Association, Norfolk, VA, USA,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015991333","display_name":"C.L. Beach","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"CL Beach","raw_affiliation_strings":["Celgene Corporation, Summit, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, NJ, USA","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003299911","display_name":"Joel Hetzer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Joel Hetzer","raw_affiliation_strings":["Celgene Corporation, Summit, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, NJ, USA","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101665484","display_name":"Qian Dong","orcid":"https://orcid.org/0000-0001-9810-1368","observed_orcids":["https://orcid.org/0000-0001-9810-1368"]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Qian Dong","raw_affiliation_strings":["Celgene Corporation, Summit, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, NJ, USA","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111658759","display_name":"Barry Skikne","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Barry S. Skikne","raw_affiliation_strings":["Celgene Corporation, Summit, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, NJ, USA","institution_ids":["https://openalex.org/I4387155837"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5003299911","https://openalex.org/A5085156317","https://openalex.org/A5101665484"],"corresponding_institution_ids":["https://openalex.org/I4387155837"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.7125,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":{"value":0.7604016,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":96},"biblio":{"volume":"122","issue":"21","first_page":"1554","last_page":"1554"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10345","display_name":"Hematopoietic Stem Cell Transplantation","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/oral-azacitidine","display_name":"oral azacitidine","score":0.8379999995231628},{"id":"https://openalex.org/keywords/myelodysplastic-syndrome","display_name":"myelodysplastic syndrome","score":0.9399999976158142},{"id":"https://openalex.org/keywords/refractory-anemia-with-excess-blasts","display_name":"refractory anemia with excess blasts","score":0.8240000009536743},{"id":"https://openalex.org/keywords/hematological-response","display_name":"hematologic response","score":0.9089999794960022},{"id":"https://openalex.org/keywords/transfusion-independence","display_name":"transfusion independence","score":0.6269999742507935},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.722000002861023},{"id":"https://openalex.org/keywords/dosing-regimen","display_name":"dosing regimen","score":0.5109999775886536},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.33500000834465027},{"id":"https://openalex.org/keywords/drug-efficacy","display_name":"drug efficacy","score":0.4560000002384186},{"id":"https://openalex.org/keywords/ipss-risk-stratification","display_name":"IPSS risk stratification","score":0.6549999713897705},{"id":"https://openalex.org/keywords/complete-remission","display_name":"complete remission","score":0.4580000042915344},{"id":"https://openalex.org/keywords/platelet-transfusion","display_name":"platelet transfusion","score":0.5550000071525574}],"concepts":[{"id":"https://openalex.org/C2776239401","wikidata":"https://www.wikidata.org/wiki/Q416451","display_name":"Azacitidine","level":5,"score":0.9170732498168945},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7612427473068237},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6729435920715332},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.6185176372528076},{"id":"https://openalex.org/C2780817109","wikidata":"https://www.wikidata.org/wiki/Q954625","display_name":"Myelodysplastic syndromes","level":3,"score":0.5602211356163025},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5350415110588074},{"id":"https://openalex.org/C2780240888","wikidata":"https://www.wikidata.org/wiki/Q6052586","display_name":"International Prognostic Scoring System","level":4,"score":0.4798823893070221},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4002261757850647},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.22917670011520386},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C150194340","wikidata":"https://www.wikidata.org/wiki/Q26972","display_name":"Gene expression","level":3,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C190727270","wikidata":"https://www.wikidata.org/wiki/Q874745","display_name":"DNA methylation","level":4,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v122.21.1554.1554","doi":"https://doi.org/10.1182/blood.v122.21.1554.1554","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v122.21.1554.1554","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2979345711","https://openalex.org/W2588146609","https://openalex.org/W2265091238","https://openalex.org/W2573724996","https://openalex.org/W2574993721","https://openalex.org/W2572473515","https://openalex.org/W2198196477","https://openalex.org/W2559398122","https://openalex.org/W2148428508","https://openalex.org/W2979538951"],"abstract_inverted_index":{"Abstract":[0],"Background":[1],"Subcutaneous":[2],"(SC)":[3],"azacitidine":[4,26,58,96,193,204,280,295,365,439,472,501],"prolongs":[5],"overall":[6],"survival":[7],"in":[8,34,61,88,165,175,186,321,426,442,481,504],"subjects":[9,35,62,73,179,185,228,267,309,313,332,341,344,371,391,421,427,448],"with":[10,36,63,74,381,428,484],"higher-risk":[11,443],"MDS":[12,39,79,271,476],"(Fenaux,":[13],"JCO,":[14],"2009).":[15],"Previous":[16],"Phase":[17,83,466],"I":[18],"and":[19,32,45,53,200,222,235,250,282,289,317,334,350,357,418,430,461,477],"II":[20],"studies":[21,85,468,492],"have":[22],"shown":[23],"extended":[24,56,437,470,499],"oral":[25,57,95,192,203,294,438,454,471,500],"dosing":[27,59,440,473,502],"schedules":[28,60,441,503],"to":[29,347,352,361,375,435,453,459],"be":[30],"safe":[31],"effective":[33],"IPSS-defined":[37],"lower-risk":[38,475],"(Garcia-Manero":[40],"et":[41],"al,":[42],"ASH":[43,46],"2010":[44],"2012).":[47],"Objective":[48],"To":[49],"assess":[50,436],"the":[51,322,382,433,496],"efficacy":[52],"safety":[54,384],"of":[55,72,107,113,139,215,233,293,386,396,446,469,489,498],"WHO-defined":[64,75],"RAEB-1":[65,76,234,429],"or":[66,77,99,104,141,145,148,177,196,262],"RAEB-2":[67,78,431],"MDS.":[68,444],"Methods":[69],"The":[70],"subset":[71],"from":[80,242],"two":[81],"ongoing":[82],"I/II":[84],"was":[86,134,162,244,298,305,328,337,366,462],"included":[87,164,320],"this":[89,114],"ad":[90],"hoc":[91],"analysis.":[92],"Subjects":[93,211],"received":[94,189,202,269],"300mg":[97,190],"QD":[98,191],"200mg":[100,205],"BID":[101,206],"for":[102],"14":[103,195,208],"21":[105,197],"days":[106],"repeated":[108],"28-day":[109],"cycles.":[110],"For":[111],"purposes":[112],"analysis,":[115],"subject":[116,359],"data":[117],"were":[118,123,223,255,345,379,404,415],"analyzed":[119],"collectively.":[120],"Hematologic":[121],"responses":[122],"defined":[124],"by":[125,307,330,339],"International":[126],"Working":[127],"Group":[128],"(IWG)":[129],"2006":[130],"criteria.":[131],"Overall":[132,166,303,323],"Response":[133,304,324],"calculated":[135],"as":[136,478],"any":[137,154],"response":[138,452],"complete":[140,159],"partial":[142],"remission":[143,160,349],"(CR":[144],"PR),":[146],"RBC":[147,326],"platelet":[149,335],"transfusion":[150],"independence":[151],"(TI),":[152],"and/or":[153,400],"hematologic":[155,451,506],"improvement":[156],"(HI).":[157],"Marrow":[158],"(mCR)":[161],"not":[163,319],"Response.":[167],"Serious":[168],"treatment-emergent":[169],"adverse":[170],"events":[171],"(STEAEs)":[172],"that":[173],"occurred":[174],"2":[176,263],"more":[178],"are":[180,318,486],"reported.":[181],"Results":[182,488],"Of":[183,389],"23":[184],"all,":[187],"20":[188],"x":[194,207,409],"days/28-day":[198,209],"cycle":[199],"3":[201,299,403],"cycle.":[210],"had":[212,230,238,268,393],"median":[213,240],"age":[214],"71":[216],"(range:":[217],"36":[218],"-":[219,247,301],"90)":[220],"years":[221],"predominantly":[224],"male":[225],"(61%).":[226],"Fourteen":[227],"(61%)":[229],"a":[231,450],"diagnosis":[232,243],"9":[236],"(39%)":[237],"RAEB-2,":[239],"time":[241],"2.1":[245],"(0.1":[246],"33.2)":[248],"months,":[249],"ECOG":[251],"performance":[252],"status":[253],"scores":[254],"0":[256],"(n=4,":[257,264],"17%),":[258],"1":[259,358],"(n=15,":[260],"65%),":[261],"17%).":[265],"Five":[266],"prior":[270],"treatments":[272],"(azacitidine":[273],"injection;":[274],"erythropoiesis":[275],"stimulating":[276],"agent":[277],"[ESA];":[278],"thalidomide;":[279],"injection":[281],"decitabine;":[283],"G-CSF,":[284],"anti-thymocyte":[285],"globulin,":[286],"methylprednisolone,":[287],"cyclosporine,":[288],"ESA).":[290],"Median":[291],"number":[292],"treatment":[296,373],"cycles":[297],"(1":[300],"29).":[302],"achieved":[306,314,329,338,449],"11/22":[308],"(50%)":[310],"(Table).":[311],"Four":[312],"mCR":[315],"only":[316],"category.":[325],"TI":[327,336],"5/12":[331],"(42%)":[333],"2/5":[340],"(40%).":[342],"Two":[343,465],"able":[346],"consolidate":[348],"proceed":[351],"allogeneic":[353],"stem":[354],"cell":[355],"transplant":[356],"progressed":[360],"AML":[362],"on-study.":[363],"Oral":[364],"generally":[367,463],"well":[368],"tolerated.":[369],"Three":[370],"discontinued":[372],"due":[374],"an":[376,394],"AE.":[377],"STEAEs":[378,414],"consistent":[380],"known":[383],"profile":[385],"SC":[387],"azacitidine.":[388],"8":[390],"who":[392],"STEAE":[395],"febrile":[397],"neutropenia,":[398],"pneumonia,":[399],"septic":[401],"shock,":[402],"severely":[405],"neutropenic":[406],"(ANC":[407],"<0.5":[408],"109/L)":[410],"at":[411],"baseline.":[412],"Other":[413],"diarrhea,":[416],"nausea,":[417],"vomiting":[419],"(n=2":[420],"each).":[422],"Conclusions":[423],"This":[424],"analysis":[425],"is":[432,457],"first":[434],"One-half":[445],"treated":[447],"azacitidine,":[455],"which":[456],"easy":[458],"administer":[460],"well-tolerated.":[464],"III":[467],"(in":[474],"maintenance":[479],"therapy":[480],"older":[482],"patients":[483],"AML)":[485],"ongoing.":[487],"these":[490],"large":[491],"will":[493],"better":[494],"elucidate":[495],"use":[497],"treating":[505],"malignancies.":[507],"Disclosures:":[508],"Gore:":[509],"Celgene":[510],"Corporation:":[511,514,523,526,529,532],"Consultancy.":[512],"Cogle:Celgene":[513],"Honoraria,":[515],"Research":[516,520],"Funding.":[517,521],"Conkling:US":[518],"Oncology:":[519],"Beach:Celgene":[522],"Employment.":[524,527,530,533],"Hetzer:Celgene":[525],"Dong:Celgene":[528],"Skikne:Celgene":[531]},"counts_by_year":[{"year":2017,"cited_by_count":1},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":1}],"updated_date":"2026-10-08T09:06:37.294493","created_date":"2016-06-24T00:00:00"}